8-K: Prestige Consumer Healthcare Reports Q3 FY26 Results

Prestige Consumer Healthcare Inc. reported Q3 FY26 revenue of $283.4 million, exceeding outlook, but saw overall revenue and EPS declines driven by Clear Eyes supply constraints.

Summary

• Q3 FY26 reported revenues were $283.4 million, a decrease of 2.4% from $290.3 million in Q3 FY25, or 2.2% excluding the impact of foreign currency.
• Q3 FY26 diluted earnings per share (EPS) were $0.97, and non-GAAP adjusted diluted EPS were $1.14, compared to $1.22 in Q3 FY25.
• For the nine months ended December 31, 2025, reported revenues totaled $807.1 million, a decrease of 4.1% from $841.2 million in YTD FY25, or 3.9% excluding foreign currency.
• YTD FY26 diluted EPS were $2.78, and non-GAAP adjusted diluted EPS were $3.16, compared to $3.28 and $3.20, respectively, in YTD FY25.
• The revenue decline was primarily attributed to lower Ear & Eye Care category sales due to limited ability to supply demand for Clear Eyes.
• The acquisition of eye care supplier Pillar5 Pharma, Inc. successfully closed in December 2025.
• Net cash provided by operating activities for YTD FY26 was $214.8 million, up from $189.7 million in YTD FY25.
• Non-GAAP free cash flow for YTD FY26 was $208.8 million, up from $184.9 million in YTD FY25.
• Approximately 0.8 million shares were opportunistically repurchased in Q3 FY26 for $45.8 million, bringing total YTD repurchases to 2.3 million shares for $155.6 million.
• Net debt as of December 31, 2025, was approximately $1.0 billion, resulting in a covenant-defined leverage ratio of 2.6x.
• The fiscal 2026 outlook was narrowed, with net sales expected to be approximately $1.1 billion (previously $1.100 to $1.115 billion) and organic revenue growth expected to decrease by approximately 3.0% (previously 1.5% to 3.0% decrease).
• Adjusted diluted EPS for FY26 is now approximately $4.54 (previously $4.54 to $4.58), and free cash flow outlook remains $245 million or more.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While the company exceeded its Q3 revenue outlook and demonstrated strong free cash flow and strategic capital allocation, the persistent revenue and EPS declines, coupled with a narrowed full-year outlook due to ongoing supply constraints and a challenging consumer environment, temper enthusiasm.

Positives

• Q3 FY26 revenue of $283.4 million exceeded the company's internal outlook.
• Clear Eyes supply improved sequentially for the second consecutive quarter, indicating progress in resolving supply constraints.
• The strategic acquisition of eye care partner Pillar5 Pharma, Inc. was successfully closed in December, which is expected to provide substantial internal supply for Clear Eyes.
• Strong year-to-date free cash flow of $208.8 million, representing a 13% increase compared to the prior year.
• The company maintains a low covenant-defined leverage ratio of 2.6x, providing significant capital allocation optionality.
• Opportunistic share repurchases totaling approximately 0.8 million shares for $45.8 million in Q3 FY26, demonstrating a commitment to shareholder value.
• The full-year fiscal 2026 free cash flow outlook of $245 million or more remains unchanged, reflecting stable financial performance.

Negatives

• Q3 FY26 reported revenues decreased 2.4% year-over-year to $283.4 million.
• YTD FY26 reported revenues decreased 4.1% year-over-year to $807.1 million.
• The revenue decline was primarily driven by limited ability to supply demand for Clear Eyes in the Ear & Eye Care category.
• Q3 FY26 diluted EPS of $0.97 and adjusted diluted EPS of $1.14 both decreased from $1.22 in the prior year comparable period.
• YTD FY26 diluted EPS of $2.78 and adjusted diluted EPS of $3.16 both decreased from $3.28 and $3.20, respectively, in the prior year comparable period.
• Adjusted EBITDA decreased 7.7% in Q3 FY26 to $90.9 million and 4.7% YTD FY26 to $257.4 million.
• The company is navigating a "challenging consumer backdrop" which has impacted year-to-date performance.
• The fiscal 2026 net sales outlook was narrowed, and the organic revenue growth outlook was revised to an approximate 3.0% decrease, indicating a more challenging top-line environment than previously anticipated.

Risks

• The impact of business and economic conditions, including evolving U.S. and international tariffs and trade actions, labor shortages, inflation, and geopolitical instability.
• Unfavorable consumer trends affecting demand for products.
• The impact of the company's advertising and marketing and new product development initiatives on sales.
• Customer inventory management initiatives that could affect order timing and volume.
• Fluctuating foreign exchange rates impacting reported financial results.
• Competitive pressures from other consumer healthcare companies.
• The ability to rapidly increase the supply of Clear Eyes from Pillar5 and other third-party suppliers to meet demand.
• The ability of the company's manufacturing operations and third-party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and supply disruption.
• The ability to pass along rising costs to customers without negatively impacting sales volumes.

Future Outlook

The company narrowed its fiscal 2026 net sales outlook to approximately $1.1 billion, reflecting a continued challenging consumer environment, and now expects an approximate 3.0% decrease in organic revenue. The outlook for adjusted diluted EPS is approximately $4.54, while the free cash flow outlook remains unchanged at $245 million or more. The company anticipates sequential improvement in Clear Eyes shipments in Q4 and expects earnings growth to reaccelerate as revenue improves.

Management Comments

• "We exceeded our third quarter revenue outlook and delivered solid profitability in the quarter, which reflected the benefits of our diverse business model and strong financial profile."
• "We are pleased with these results, especially when navigating the challenging consumer backdrop we’ve experienced year-to-date."
• "As expected, we continued to make progress toward improving Clear Eyes supply, increasing sales sequentially and closing on the acquisition of Pillar5 in December."
• "Furthermore, our superior free cash flow and low leverage allowed us to repurchase approximately 0.8 million shares in the third quarter to further enhance shareholder value."
• "Looking ahead we continue to rebuild our supply chain capacity for Clear Eyes and expect supply improvements in coming quarters to support long-term demand."
• "We continue to remain focused on brand-building that drives long-term organic growth, along with disciplined capital allocation that helps generate superior shareholder value creation over time."

Industry Context

StockSavvy.ai notes that Prestige Consumer Healthcare's performance reflects broader challenges in the consumer goods sector, particularly related to supply chain resilience and fluctuating consumer demand. The strategic acquisition of Pillar5 Pharma highlights a trend towards vertical integration to secure critical supply, a common response to recent global supply disruptions. The company's focus on brand-building and disciplined capital allocation, including share repurchases, aligns with strategies employed by mature consumer healthcare companies to drive shareholder value amidst market volatility.

Comparison to Industry Standards

• The company's year-to-date Free Cash Flow (FCF) of $208.8 million, up 13% versus the prior year, demonstrates strong cash generation capabilities.
• The LTM (Last Twelve Months) FCF Yield of 7% to 8% is noted as being in line with or slightly above a peer group including CHD, CL, PG, HLN, UL, EPC, CLX, PRGO, RKT, KVUE, indicating efficient cash conversion relative to its market capitalization.
• The covenant-defined leverage ratio of 2.6x is considered low, providing ample capacity for strategic capital allocation, including M&A and share repurchases, which is favorable compared to highly leveraged industry peers.

Stakeholder Impact

• Shareholders: Impacted by lower EPS, but potentially benefit from share repurchases and strategic acquisition aimed at long-term value creation.
• Customers: May experience continued limited availability of Clear Eyes products until supply chain issues are fully resolved, but sequential improvements are noted.
• Suppliers: Pillar5 Pharma, Inc. becomes a key internal supplier, indicating a shift in supply chain strategy, while additional third-party suppliers are also being utilized.
• Employees: No direct impact on employment or compensation is mentioned, but operational adjustments related to supply chain and acquisition integration may occur.

Next Steps

• Continue to rebuild supply chain capacity for Clear Eyes.
• Invest to accelerate Pillar5 production capacity, particularly on new high-speed lines.
• Re-expand Clear Eyes SKU assortment.
• Gradually rebuild retailer and PBH safety stocks for Eye Care products.
• Reaccelerate distribution through supply confidence and robust marketing for Eye Care products.
• Host a conference call on February 5, 2026, to review results.
• Continue brand-building to drive long-term organic growth.
• Continue disciplined capital allocation to generate superior shareholder value.
• Pursue M&A that is attractive to shareholders.
• Further net deleveraging to enhance optionality.
• Near-term cash build to enhance future capital flexibility.

Key Dates

Recommendation

The company faces ongoing revenue and EPS declines due to supply constraints and a challenging consumer environment, leading to a narrowed outlook. However, strong free cash flow, strategic share repurchases, and the Pillar5 acquisition provide a foundation for future recovery. The stock is a "hold" as investors await clearer signs of sustained revenue growth and full resolution of supply issues, particularly for Clear Eyes, before considering a more aggressive stance.

Keywords

Prestige Consumer Healthcare, PBH, Q3 earnings, fiscal 2026, financial results, consumer healthcare, Clear Eyes, Pillar5 acquisition, share repurchase, revenue, EPS, free cash flow, OTC, eye care, supply chain